Silke Oßwald

phone +49 30 94793 104

Press Releases

Entry from: 21.03.2018  
Category: News, Press Releases


EU-OPENSCREEN ERIC is officially announced in the European Official Journal of the EU. The Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) is involved in the setting up of the infrastructure in Germany, which is funded by the Federal Ministry of (...)[more]

Entry from: 19.03.2018  
Category: News, Press Releases

Start-up Tubulis Technologies erhält Leibniz-Gründerpreis 2018

Das gemeinsame Gründungsvorhaben Tubulis Technologies des Leibniz-Forschungsinstituts für Molekulare Pharmakologie (FMP) und der Ludwig-Maximilians-Universität München (LMU) ist mit dem Gründerpreis der Leibniz-Gemeinschaft 2018 ausgezeichnet worden. Die Gründer (...)[more]

Entry from: 02.03.2018  
Category: News, Press Releases

How to Overcome the Blood Brain Barrier

The blood brain barrier is a mighty obstacle. Some substances in the blood are toxic to the sensitive brain. The barrier protects the brain and prevents these substances from crossing into the brain environment. While this is of great benefit, the barrier also (...)[more]

Entry from: 19.02.2018  
Category: News, Press Releases

A Matter of Dynamics

Most ion channels are very selective about the ions, which may or may not pass through them. They may be conductive for potassium ions and non-conductive for sodium ions or vice versa. However, a number of ion channels allows for the efficient passage of both (...)[more]

Entry from: 05.02.2018  
Category: News, Press Releases, Research Highlights

How a Mutated Gene Triggers Hypertension

Arterial hypertension (high blood pressure) can occur when the adrenal cortex produces excess aldosterone hormone. How does this happen? Scientists working at the Leibniz Institute for Molecular Pharmacology (FMP) and the Max Delbrück Center for Molecular (...)[more]

Entry from: 07.12.2017  
Category: Press Releases, News

Molecular Chaperones Shown to Assist in the Fight against Huntington Disease

Huntington’s disease is a neurodegenerative disease. It is always fatal. The disease is caused by a defect in the Huntingtin gene. To this day, no therapy will put a stop to the insidious disintegration of brain cells. Fortunately, scientists of the (...)[more]

Entry from: 04.12.2017  
Category: News, Press Releases

Volker Haucke is a new member of the Berlin-Brandenburg Academy of Sciences and Humanities (BBAW)

Volker Haucke is a newly elected member of the Berlin-Brandenburg Academy of Sciences and Humanities. In their board sessions on Einstein Day 2017, the members of the BBAW elected Volker Haucke full member of the academy. [more]

Entry from: 11.10.2017  
Category: News, Press Releases

Making a Super-TARP for Super-activation

Biophysicist Professor Dr. Andrew Plested works at the Leibniz Institute for Molecular Pharmacology in Berlin (Germany). He is hot on the trail of a new mechanism of the synaptic function. Last year, Professor Plested's group was able to demonstrate the (...)[more]

Entry from: 01.09.2017  
Category: News, Press Releases

The point of release is the key: Identification of a key molecule for the neurotransmitter release in synapses

The contact areas between nerve cells are called synapses. What happens there lies at the heart of communication between nerve cells. Communication starts with the release of chemical messengers known as neurotransmitters at these synapses. (...)[more]

Entry from: 07.07.2017  
Category: News, Press Releases

Toward New Antiviral Drugs and Antibiotics

Scientists at Freie Universität Berlin and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) have succeeded in revealing a key mechanism of membrane deformation. “This mechanism plays a fundamental role in cell entry of receptors and hormones and (...)[more]


Leibniz-Forschungsinstitut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP)
Campus Berlin-Buch
Robert-Roessle-Str. 10
13125 Berlin, Germany
+4930 94793 - 100 
+4930 94793 - 109 (Fax)

Like many sites, we use cookies to optimize the user's browsing experience. Data Protection OK